Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease
- PMID: 9371983
- DOI: 10.1097/00062752-199502020-00005
Erythrocyte dehydration in pathophysiology and treatment of sickle cell disease
Abstract
A prominent feature of sickle cell disease is the presence of cells with markedly increased sickle cell hemoglobin concentration, as a consequence of the loss of potassium, chloride, and water from the erythrocyte. Because of the extreme dependency of the kinetic of polymerization on sickle cell hemoglobin concentration, these dehydrated erythrocytes have an increased tendency to polymerize and sickle. Thus blockade of the loss of potassium from the erythrocyte should prevent the increase in sickle cell hemoglobin concentration and reduce sickling. The availability of this potential therapeutic option is based on a detailed knowledge of the mechanisms leading to cell dehydration. Two ion transport pathways, the K-Cl cotransport and the Ca(2+)-activated K+ channel, play a prominent role in the dehydration of sickle erythrocytes. Possible therapeutic strategies include inhibition of K-Cl cotransport by increasing erythrocyte Mg2+ content and inhibition of the Ca(2+)-activated K channel by oral administration of clotrimazole.
Similar articles
-
Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease.J Clin Invest. 1996 Mar 1;97(5):1227-34. doi: 10.1172/JCI118537. J Clin Invest. 1996. PMID: 8636434 Free PMC article.
-
Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease.J Clin Invest. 1997 Oct 1;100(7):1847-52. doi: 10.1172/JCI119713. J Clin Invest. 1997. PMID: 9312186 Free PMC article. Clinical Trial.
-
Therapeutic strategies for prevention of sickle cell dehydration.Blood Cells Mol Dis. 2001 Jan-Feb;27(1):71-80. doi: 10.1006/bcmd.2000.0366. Blood Cells Mol Dis. 2001. PMID: 11358364 Review.
-
Sickle cell disease: from membrane pathophysiology to novel therapies for prevention of erythrocyte dehydration.J Pediatr Hematol Oncol. 2003 Dec;25(12):927-33. doi: 10.1097/00043426-200312000-00004. J Pediatr Hematol Oncol. 2003. PMID: 14663274 Review.
-
Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.J Clin Invest. 1994 Apr;93(4):1670-6. doi: 10.1172/JCI117149. J Clin Invest. 1994. PMID: 7512989 Free PMC article.
Cited by
-
Kinetics of sickle cell biorheology and implications for painful vasoocclusive crisis.Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1422-7. doi: 10.1073/pnas.1424111112. Epub 2015 Jan 20. Proc Natl Acad Sci U S A. 2015. PMID: 25605910 Free PMC article.
-
Headache and Facial Pain in Sickle Cell Disease.Curr Pain Headache Rep. 2016 Mar;20(3):20. doi: 10.1007/s11916-016-0546-z. Curr Pain Headache Rep. 2016. PMID: 26879878 Review.
-
Regulated phosphorylation of the K-Cl cotransporter KCC3 is a molecular switch of intracellular potassium content and cell volume homeostasis.Front Cell Neurosci. 2015 Jul 9;9:255. doi: 10.3389/fncel.2015.00255. eCollection 2015. Front Cell Neurosci. 2015. PMID: 26217182 Free PMC article.
-
Intravenous fluid therapy and hospital outcomes for vaso-occlusive episodes in children, adolescents, and young adults with sickle cell disease.Pediatr Blood Cancer. 2024 Feb;71(2):e30781. doi: 10.1002/pbc.30781. Epub 2023 Nov 27. Pediatr Blood Cancer. 2024. PMID: 38015105 Free PMC article.
-
Fluid overload due to intravenous fluid therapy for vaso-occlusive crisis in sickle cell disease: incidence and risk factors.Br J Haematol. 2021 Sep;194(5):899-907. doi: 10.1111/bjh.17696. Epub 2021 Jul 15. Br J Haematol. 2021. PMID: 34263922 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous